SureNano Science Ltd (SURE) AI Stock Analysis

• Market Cap: C$9.83M
• Dividend Yield: N/A
• Average Volume (3M): 666.00
• Price to Earnings (P/E): ―
• Beta (1Y): -2.33
• Revenue Growth: N/A
• EPS Growth: 91.27%
• Country: CA
• Employees: N/A
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Chemicals - Specialty
• EPS (TTM): -0.01
• Shares Outstanding: 33,907,800
• 10 Day Avg. Volume: 950
• 30 Day Avg. Volume: 666
• PEG Ratio: 0.37
• Price to Book (P/B): -21.52
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -10.64
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: C$0.28 ▼(-7.67% Downside)
• Action: Reiterated Date: 03/10/26
• Date: Action: Reiterated 03/10/26

The score is driven primarily by very weak financial performance (no recent revenue, ongoing losses and cash burn, and negative equity). Technicals add further caution with a generally bearish trend and negative MACD, only slightly tempered by oversold-leaning RSI/Stoch readings. Valuation provides limited support due to the company being loss-making and no dividend yield data.

Positive Factors

Low Leverage

The absence of reported debt materially lowers immediate refinancing and interest burdens, giving management structural flexibility. Over a multi-month horizon this reduces default risk, allows more time to pursue partnerships or corrective actions, and can make future capital raises less costly if operations stabilize.

Historic Gross Margin

Strong gross profit in 2021–2022 implies favorable unit economics for the company’s products or processes. If the firm can restore revenue, those structural margins could support operating leverage and faster path to profitability, making recovered sales more valuable to long-term earnings sustainability.

Improving Cash Burn Trend

A reduction in cash burn between 2023 and 2024 indicates management has taken actions to curb outflows or improve efficiency. Sustained improvement in cash consumption extends runway, lowers near‑term funding needs and improves the odds of reaching self‑funding or securing less dilutive strategic capital over the coming months.

Negative Factors

Absent Revenue

A multiyear absence of revenue destroys the company’s ability to generate operating cash and demonstrate product-market fit. Without recurring top-line, there is no base to absorb fixed costs or scale, making any recovery contingent on restarting sustainable sales—a significant structural headwind.

Negative Equity

Negative and worsening shareholders’ equity signals accumulated losses and a weakened capital base, constraining financing options and increasing insolvency risk. Over months, this typically forces dilutive recapitalizations or distressed financing, reducing strategic flexibility and harming long‑term stakeholder prospects.

Chronic Cash Burn

Persistent negative operating and free cash flow shows the business is not self‑funding and relies on external capital. Continued cash burn pressures management to raise funds—often dilutive—restricts investment in growth or commercialization, and leaves viability dependent on successful financing or a rapid operational turnaround.

SureNano Science Ltd Business Overview & Revenue Model

Company Description

SureNano Science Ltd. operates as a nanotechnology supply company in Canada and Colorado, the United States. The company distributes SureNano surfactant, a ready-to-mix food-grade compound that provides the base for high performance hemp and cannabis nano-emulsions. Its SureNano surfactant has applications in products, such as CBD, hemp-infused sprays, beverages, food items, and tropical products. The company was incorporated in 2021 and is headquartered in Vancouver, Canada.

How the Company Makes Money

null

SureNano Science Ltd Financial Statement Overview

Summary

Financial profile is very weak: losses persist with negative EBIT/EBITDA, revenue is effectively zero in 2023–2025, and operating/free cash flow are negative each year. While no reported debt reduces near-term refinancing risk, negative and worsening equity plus shrinking assets signal significant balance-sheet stress and reliance on external funding.

Income Statement

Operating performance remains weak: the company has reported losses in every year shown, with negative EBIT/EBITDA throughout. Revenue has effectively disappeared in the last three annual periods (2023–2025 revenue at 0), limiting visibility on the path to profitability. A positive from earlier years is that gross profit was strong when revenue existed (2021–2022), but the current run-rate shows no meaningful top-line to absorb fixed costs, keeping earnings deeply negative.

Balance Sheet

Leverage appears low on the surface with no reported debt across periods, which reduces near-term financial risk from interest and refinancing. However, the balance sheet has deteriorated sharply: shareholders’ equity turned negative in 2024 and fell further in 2025, signaling accumulated losses and a weakened capital base. Total assets have also contracted materially versus 2021–2023 levels, reducing financial flexibility and increasing reliance on future financing to sustain operations.

Cash Flow

Cash generation is consistently negative: operating cash flow and free cash flow are below zero in every year shown, indicating ongoing cash burn. While cash burn improved from 2023 to 2024 and remains better than the 2022 peak outflow, 2025 still shows substantial negative operating and free cash flow, suggesting the business is not self-funding. The company’s cash flow profile implies continued dependence on external capital unless operations materially improve.

Breakdown	TTM	Mar 2024	Jun 2023	Jun 2022	Mar 2022	Mar 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	18.00K	36.00K
Gross Profit	-1.88K	-2.50K	-2.50K	-3.75K	16.51K	34.66K
EBITDA	-407.27K	-57.09K	-277.39K	-380.27K	-1.12M	-81.59K
Net Income	-226.77K	-59.59K	-279.89K	-384.02K	-1.12M	-82.51K
Balance Sheet
Total Assets	1.20M	54.27K	153.11K	317.61K	686.44K	966.81K
Cash, Cash Equivalents and Short-Term Investments	1.17M	23.49K	134.80K	276.99K	667.09K	929.01K
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	34.16K	134.04K	173.29K	57.90K	36.49K	17.32K
Stockholders Equity	1.17M	-79.77K	-20.18K	259.71K	649.95K	949.49K
Cash Flow
Free Cash Flow	-208.53K	-161.31K	-142.19K	-403.63K	-669.76K	-102.99K
Operating Cash Flow	-208.53K	-161.31K	-142.19K	-383.63K	-669.76K	-102.99K
Investing Cash Flow	0.00	0.00	0.00	-6.47K	0.00	0.00
Financing Cash Flow	1.39M	50.00K	0.00	0.00	407.85K	1.03M

SureNano Science Ltd Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.30
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:SURE, the sentiment is Positive. The current price of 0.3 is above the 20-day moving average (MA) of 0.29, below the 50-day MA of 0.31, and above the 200-day MA of 0.18, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 51.41 is Neutral, neither overbought nor oversold. The STOCH value of 36.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:SURE.

SureNano Science Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VNP	76 Outperform	C$2.55B	22.34	26.65%	―	30.36%	181.15%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
NEO	50 Neutral	C$1.06B	108.72	-1.58%	2.55%	8.04%	-195.66%
GMG	44 Neutral	C$268.52M	-3.44	-414.40%	―	6.29%	-3.71%
CNO	42 Neutral	C$13.88M	-2.61	-86.94%	―	-15.84%	-375.96%
NANO	42 Neutral	C$106.41M	-4.53	-64.75%	―	―	56.03%
SURE	41 Neutral	C$9.83M	-6.54	―	―	―	91.27%

SureNano Science Ltd Corporate Events

SureNano Buys GlucaPharm to Drive Next-Generation GLP-1 Drug Push

SureNano Science Ltd. has completed the acquisition of GlucaPharm Inc., gaining control of GEP44, a patented, second-generation GLP peptide that has shown significant weight-loss and blood-glucose benefits in preclinical studies with fewer gastrointestinal side effects than first-generation drugs such as Ozempic and Mounjaro. The all-share deal, which includes locked-up stock and warrants, accelerates SureNano’s shift into a near-term pharmaceutical value creator and is supported by the appointment of veteran drug developer Dr. Nihar R. Pandey as director and chief scientific officer.

GlucaPharm’s program targets the rapidly expanding GLP market with a differentiated asset that may be deliverable via non-injectable routes such as oral, sublingual or nasal formulations, a feature management believes could broaden patient adoption and deepen market penetration. The company is working with an Australian contract research organization to advance an IND-enabling FDA study and a Phase I trial in Australia, with key regulatory and early clinical milestones expected over the next six to nine months, positioning SureNano to compete in one of the decade’s most lucrative pharmaceutical segments.

The most recent analyst rating on (TSE:SURE) stock is a Hold with a C$0.30 price target. To see the full list of analyst forecasts on SureNano Science Ltd stock, see the TSE:SURE Stock Forecast page.